mercredi 15 mars 2017

Onco Actu du 15 mars 2017

1. Biologie

Mechanism triggers spread of prostate cancer to bones [WSU]

3.1.1 Tabac - e-cigs

Battery Safety Concerns in Electronic Nicotine Delivery Systems (ENDS) Public Workshop - April 2017 [FDA]

4. Dépistage, diagnostic et pronostic

Beyond colour vision – spotting cancer when it hides between the red, green and blue [Cancer Research UK]

5. Traitements

Using a ‘kiss of death’ to neutralize disease-causing proteins [FierceBiotech]

5.10 Traitements - Essais

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results [The Street]

Tesaro shares skid lower as AstraZeneca wows with PhIII data on PARP drug for ovarian cancer [EndPoints]

AstraZeneca ovarian cancer drug slows disease markedly in study [Reuters]

5.12 Immunothérapies

Tasmanian Devil Cancer Immunotherapy [The Scientist]

5.12.2 Immunothérapies - CAR-T

Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy [Kite]

5.2.3 Pharma - économie

Top 15 pharma companies by 2016 revenue [FiercePharma]

Pushing ahead with cancer drug research, Peloton brings its latest round to $75M [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

Astex bags milestone after Novartis cancer drug approved [FierceBiotech]

FDA OKs Merck’s Keytruda for Hodgkin lymphoma, a first in blood cancer [EndPoints]

Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance [Reuters]

Merck's Keytruda wins FDA nod for treating blood cancer [Reuters]

5.5 ASCO

Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care for Patients [ASCO]

6.1 Observation

Survivors of Hodgkin lymphoma over twice as likely to suffer second cancer [Pharmafile]

Hodgkin lymphoma survivors at high risk of second cancers [Institute of Cancer Research]

6.11 Patients

Putting the Cancer Patient Front and Center: An Interview with NCI’s Dr. Paul Jacobsen [NCI]

6.9 Controverses

How Do We Protect Patients From False Promises In Right-To-Try Laws? [Health Affairs Blog]